Global Pharma Major Deals Report: January–April 2025
Johnson & Johnson
Medical Device R&D and Manufacturer
| Lead Rise Individual Thigh |
Name | Relevant | Price Change Range |
|---|---|---|---|
| Haiwang Bio | Research Report Cash Flow | 9.83% | |
| First Medicine | Research Report Cash Flow | 5.46% | |
| Thermo Fisher Scientific | Research Report Cash Flow | 4.31% | |
| People's Tongtai | Research Report Capital Flow | 2.66% | |
| Click to view all>> | |||
| Resources Gold Flow Entry |
Name | Relevant | Net Inflow (10,000) |
|---|---|---|---|
| Haiwang Bio | Research Report Cash Flow | 7608.83 | |
| Zhejiang Zhenyuan | Research Report Cash Flow | 508.83 | |
| Kai Kai Industry | Research Report Cash Flow | 458.25 | |
| Sinopharm Accord | Research Report Cash Flow | 454.70 | |
| Click to view all>> | |||
Major Deals of Global Pharmaceutical Companies from January to April 2025
By entering the search module through Synapse, the intelligence database of Smart Bud, clicking on drug transactions, and setting specific conditions such as total amount exceeding 10 billion US dollars and date starting from January 1, 2025, we found 21 significant pharmaceutical enterprise transactions meeting the criteria, including acquisitions and mergers. These transactions involve more than 10 drugs, among which one has been approved for marketing, and two are in Phase 2 clinical trials, etc.
1. Johnson & Johnson Acquires Intra-Cellular Therapies for Up to $14.6 Billion
On April 2, Johnson & Johnson announced that it had completed the acquisition of Intra-Cellular Therapies. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit of Johnson & Johnson Innovative Medicine [1]. On January 13, Johnson & Johnson announced that it had reached a definitive agreement with Intra-Cellular Therapies, under which Johnson & Johnson would acquire all outstanding shares of Intra-Cellular Therapies for $132.00 per share in cash. This biopharmaceutical company focuses on developing and commercializing treatments for central nervous system (CNS) disorders, with a total equity value of approximately $14.6 billion [2].
Through this acquisition, Johnson & Johnson adds CAPLYTA® (lumateperone) to its robust portfolio of differentiated pharmaceuticals.
CAPLYTA is an oral therapy taken once daily, approved for the treatment of schizophrenia in adults. It is also the first and only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression), as both monotherapy and adjunctive therapy to lithium or valproate.
A Phase 3 study (NCT04285515, Study403) of CAPLYTA, a randomized, double-blind, placebo-controlled, multicenter clinical trial, met its primary endpoint. These trials aimed to evaluate its efficacy and safety in treating patients with major depressive disorder (MDD) and bipolar depression (BD) with mixed features [3].
CAPLYTA significantly improved the MADRS total scores in patients with comorbid MDD/bipolar depression, standalone MDD, and standalone bipolar depression. Compared with placebo, the least squares mean difference (LSMD) in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 43 was -5.7 for comorbid MDD/bipolar depression, -5.9 for standalone MDD, and -5.7 for standalone bipolar depression.
Moreover, in two pivotal global, double-blind, placebo-controlled Phase 3 clinical trials (Study 501 and Study 502), CAPLYTA, as an adjunctive treatment to antidepressants, demonstrated statistically significant and clinically meaningful improvements in depressive symptoms, as measured by clinician ratings and patient-reported outcomes. The safety profile of CAPLYTA in both studies was consistent with its existing clinical data, with no new safety concerns identified.